We are live on ! Find out more
SAM

Senzar Asset Management Portfolio holdings

AUM $34.7M
1-Year Est. Return 0.56%
This Fund
S&P 500
This Quarter Est. Return
+17.41%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$395M
AUM Growth
+$17.6M
Cap. Flow
-$3.26M
Cap. Flow %
-0.82%
Top 10 Hldgs %
70.4%
Holding
40
New
10
Increased
13
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
HALO icon
Halozyme
HALO
+$28.6M
2
GILD icon
Gilead Sciences
GILD
+$22.5M
3
BIVV
Bioverativ Inc. Common Stock
BIVV
+$16.9M
4
SNY icon
Sanofi
SNY
+$12.9M
5
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$12.7M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$40.3M
2
SHPG
Shire pic
SHPG
+$33.5M
3
AGN
Allergan plc
AGN
+$33.3M
4
TSRO
TESARO, Inc.
TSRO
+$19.1M
5
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 93.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNY icon
1
Sanofi
SNY
$105B
$69.6M 17.64%
1,538,908
+304,708
+25% +$12.9M
HALO icon
2
Halozyme
HALO
$9.23B
$45.2M 11.46%
3,489,864
+2,264,420
+185% +$28.6M
ESRX
3
DELISTED
Express Scripts Holding Company
ESRX
$34.5M 8.74%
523,301
+76,300
+17% +$5.25M
ELV icon
4
Elevance Health
ELV
$84.4B
$28.2M 7.14%
170,450
-45,050
-21% -$7.17M
GILD icon
5
Gilead Sciences
GILD
$162B
$21.8M 5.52%
+320,600
New +$22.5M
BIVV
6
DELISTED
Bioverativ Inc. Common Stock
BIVV
$18.7M 4.74%
+343,800
New +$16.9M
ABT icon
7
Abbott
ABT
$175B
$17.2M 4.35%
386,800
+190,500
+97% +$8.24M
MDXG icon
8
MiMedx Group
MDXG
$621M
$16.1M 4.09%
1,692,850
+447,300
+36% +$3.78M
TGTX icon
9
TG Therapeutics
TGTX
$8.06B
$13.3M 3.36%
+1,139,900
New +$8.18M
GMED icon
10
Globus Medical
GMED
$10.2B
$13.2M 3.36%
+447,100
New +$12.2M
FWP
11
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$10.2M 2.57%
+67,471
New +$12.7M
MYGN icon
12
Myriad Genetics
MYGN
$535M
$9.96M 2.52%
518,800
+23,700
+5% +$420K
LPNT
13
DELISTED
LifePoint Health, Inc.
LPNT
$9.39M 2.38%
+143,400
New +$8.86M
SEM
14
DELISTED
Select Medical
SEM
$8.84M 2.24%
+1,229,043
New +$8.91M
NDRM
15
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$8.59M 2.18%
323,700
+136,900
+73% +$3.39M
THC icon
16
Tenet Healthcare
THC
$16.8B
$8.58M 2.17%
+484,300
New +$8.98M
VTRS icon
17
Viatris
VTRS
$19.8B
$8.45M 2.14%
+216,700
New +$8.74M
TVTX icon
18
Travere Therapeutics
TVTX
$5.23B
$7.94M 2.01%
430,189
-62,700
-13% -$1.23M
OFIX icon
19
Orthofix Medical
OFIX
$445M
$7.21M 1.83%
188,908
+77,533
+70% +$2.87M
CNCE
20
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$7.11M 1.8%
416,845
+16,257
+4% +$195K
DPLO
21
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$7.1M 1.8%
+445,200
New +$6.42M
CORI
22
DELISTED
Corium International, Inc.
CORI
$6.3M 1.6%
1,508,266
-68,500
-4% -$251K
ALDR
23
DELISTED
Alder Biopharmaceuticals
ALDR
$4.47M 1.13%
215,070
+90,500
+73% +$2M
MNTA
24
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.18M 1.06%
313,296
-218,602
-41% -$3.42M
ARNA
25
DELISTED
Arena Pharmaceuticals Inc
ARNA
$2.85M 0.72%
195,289
+7,540
+4% +$112K
1
2

Similar funds

BCP
Blum Capital Partners San Francisco, California $34.1M AUM 1.14% 1-Year Est. Return
PRHC
P.R. Herzig & Co Roslyn Heights, New York $45.9M AUM 15.88% 1-Year Est. Return
NAM
Needelman Asset Management Ladera Ranch, California $46M AUM 8.27% 1-Year Est. Return
GG
Gores Group Beverly Hills, California $22.3M AUM 4.58% 1-Year Est. Return
SM
SLS Management New York $17.2M AUM 14.82% 1-Year Est. Return
BC
Breogan Capital New York $56.4M AUM
SCPM
Social Capital PEP Management Palo Alto, California $56.5M AUM
FAM
Fortaleza Asset Management Chicago, Illinois $12.3M AUM 48.33% 1-Year Est. Return

Senzar Asset Management's Q1 2017 Portfolio in Review

As of Q1 2017, Senzar Asset Management held 40 positions worth $395M, up 4.7% from $377M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Senzar Asset Management's Q1 2017 filing shows 10 new, 13 increased, 5 reduced and 12 closed positions. Its largest new stake was Gilead Sciences: 320,600 shares worth $21.8M. The largest sale was Eli Lilly, an estimated $40.3M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier.

  • Senzar Asset Management's largest Q1 2017 buy was Gilead Sciences: 320,600 shares worth $21.8M.
  • Senzar Asset Management added most to Halozyme in Q1 2017, an estimated $28.6M increase.
  • Senzar Asset Management's biggest Q1 2017 reduction was Elevance Health, cutting an estimated $7.17M.
  • Senzar Asset Management fully exited Eli Lilly in Q1 2017, selling an estimated $40.3M.
  • Senzar Asset Management's ten largest holdings make up 70% of its $395M portfolio in Q1 2017.
  • Senzar Asset Management opened 10 new positions and closed 12 in Q1 2017.
  • Senzar Asset Management's portfolio value rose 4.7% quarter-over-quarter to $395M.

Based on Senzar Asset Management's 13F filing for Q1 2017, filed 12 May 2017.